Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.

MLA

Rolland D, et al. “Phase II Trial and Prediction of Response of Single Agent Tipifarnib in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Groupe d’Etude Des Lymphomes de l’Adulte Trial.” Cancer Chemotherapy & Pharmacology, vol. 65, no. 4, Mar. 2010, pp. 781–90. EBSCOhost, https://doi.org/10.1007/s00280-009-1185-4.

APA

Rolland D, Ribrag V, Haioun C, Ghesquieres H, Jardin F, Bouabdallah R, Franchi P, Briere J, De Kerviler E, Chassagne-Clement C, Raponi M, Houlgatte R, Jais JP, Thieblemont C, Rolland, D., Ribrag, V., Haioun, C., Ghesquieres, H., Jardin, F., & Bouabdallah, R. (2010). Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial. Cancer Chemotherapy & Pharmacology, 65(4), 781–790. https://doi.org/10.1007/s00280-009-1185-4

Chicago

Rolland D, Ribrag V, Haioun C, Ghesquieres H, Jardin F, Bouabdallah R, Franchi P, et al. 2010. “Phase II Trial and Prediction of Response of Single Agent Tipifarnib in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Groupe d’Etude Des Lymphomes de l’Adulte Trial.” Cancer Chemotherapy & Pharmacology 65 (4): 781–90. doi:10.1007/s00280-009-1185-4.